MedTrace Logo

Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage

NCT02915380 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-09-27

No results posted yet for this study

Summary

Recently, the occurrence and potential impact of pituitary dysfunction after aSAH has gained increasing interest. Several studies have demonstrated pituitary dysfunction after SAH suggesting that pituitary dysfunction may be a contributing factor for residual symptoms after SAH. This is an observational multicentric study aimed to test the prevalence of thyroid abnormalities, other neuroendocrinological dysfunction and their influence on outcome of patients affected by aSAH.

Conditions

  • Thyroid Disfunction
  • Subarachnoid Haemorrhage From Cerebral Aneurism Rupture
  • Pituitary Disfunction

Interventions

BIOLOGICAL

Evaluation of pituitary endocrine function

The basal thyroid hormone and test to perform will be: TSH, fT4, fT3. When available, the following hormones will be tested: FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality. Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)

BEHAVIORAL

Evaluation of clinical outcome

Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.

BEHAVIORAL

Evaluation of neuropsychological function

Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Dr. Rita Bertuetti

    lead OTHER

Principal Investigators

  • Chiara Robba, MD · Cambridge University Hospitals NHS Foundation Trust

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-01-31
Completion
2018-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02915380 on ClinicalTrials.gov